Bentracimab (formerly PB2452 or MEDI2452) represents a major shift in the management of antiplatelet therapy. While the P2Y12 inhibitor ticagrelor (Brilinta®) is a cornerstone in treating acute coronary syndromes, its reversible binding nature has historically lacked a dedicated reversal agent—until now.

For researchers and clinicians, bentracimab offers a targeted solution for a high-stakes clinical dilemma: how to rapidly restore hemostasis in patients requiring emergency surgery or facing life-threatening hemorrhage.

Ticagrelor is a potent, direct-acting P2Y12 receptor antagonist. Unlike clopidogrel or prasugrel, which bind irreversibly to platelets, ticagrelor’s binding is reversible. However, this does not mean its effects wear off instantly; the drug and its active metabolite have half-lives that necessitate a 3–5 day "washout" period before elective surgery.

In emergency scenarios, platelet transfusions are often ineffective because circulating ticagrelor simply binds to the new platelets. Bentracimab was developed to fill this "reversal gap," providing a way to bypass the washout period when time is of the essence.

Bentracimab is a recombinant human monoclonal antibody antigen-binding fragment (Fab).

• Origin: Originally developed by MedImmune (AstraZeneca) and later licensed to PhaseBio Pharmaceuticals. Following restructuring, the program assets were transferred to SFJ Pharmaceuticals, with SERB Pharmaceuticals managing U.S. commercialization.

• Structure: As a Fab fragment, it lacks the Fc region of a full antibody. This design choice is intentional: it facilitates a smaller molecular size for better tissue distribution and prevents Fc-mediated effector functions (like complement activation) that are unnecessary for its neutralizing mission.

• Target: It is highly specific for ticagrelor and its major active metabolite, AR-C124910XX.

The mechanism of bentracimab is elegant in its simplicity: it acts as a high-affinity "decoy" receptor.

1. High Affinity Binding: Bentracimab binds to free ticagrelor with an affinity approximately 100-fold greater than ticagrelor’s affinity for the P2Y12 receptor.

2. Scavenging: By sequestering free ticagrelor and its active metabolite in the blood, bentracimab shifts the equilibrium, causing ticagrelor to dissociate from the P2Y12 receptors on the platelets.

3. Restoration: Once the receptors are cleared of the inhibitor, normal platelet aggregation can resume.

Because it is highly specific, it does not bind to other P2Y12 inhibitors like clopidogrel or prasugrel, nor does it interfere with other aspects of the coagulation cascade.

The efficacy of bentracimab was primarily established through the REVERSE-IT (Rapid and SustainEd ReVERSal of TicagrElor – Intervention Trial) Phase 3 study. Key findings include:

• Rapid Onset: Reversal of platelet inhibition is observed within 5 to 10 minutes of initiating the intravenous infusion.

• Sustained Effect: The dosing regimen (typically a bolus followed by a loading and maintenance infusion) maintains normalized platelet function for 20–24 hours.

• Hemostasis Success: In the REVERSE-IT trial, effective hemostasis was achieved in 100% of patients requiring urgent surgery and over 83% of patients with major bleeding.

Clinical data suggests that bentracimab is generally well-tolerated.

• Non-Prothrombotic: Importantly, bentracimab reverses the drug effect without causing a "rebound" prothrombotic state.

• Adverse Events: The most common side effects reported are minor, such as infusion site pain.

• Thrombotic Risk: Thrombotic events observed in trials (approx. 4%) were consistent with the high-risk cardiovascular profiles of the patients being studied, rather than being attributed to the antibody itself.

As of 2025/2026, bentracimab has reached several major regulatory milestones:

• FDA Status: It received Breakthrough Therapy Designation and has been under Priority Review following a Biologics License Application (BLA) submission.

• EMA Status: It was granted PRIME (PRIority MEdicines) designation in the EU.

• Orphan Drug Designation: Granted in March 2025 for specific emergency reversal indications.

The future of bentracimab lies in its potential to change the "standard of care" for P2Y12 management, giving clinicians the confidence to use potent antiplatelet agents knowing a "switch" exists to turn them off in an emergency.

At ichorbio, we understand that access to cutting-edge antibodies is vital for preclinical and comparative research.

We supply Bentracimab as a custom research product.

• Delivery Time: 4 weeks.

• Format: Available in various sizes tailored to your laboratory requirements